<DOC>
	<DOCNO>NCT00275444</DOCNO>
	<brief_summary>A dose defining study protease inhibitor tipranavir ( TPV ) , boost low dose ritonavir ( RTV ) . Three dose combination TPV/RTV administer multiple antiretroviral experience patient dose achieves best efficacy safety determine evaluation 2 , 8 , 24-week virologic response adverse event laboratory profile measure would select clinical study .</brief_summary>
	<brief_title>3 TPV/RTV Doses Multiple ARV Experienced Patients - Tipranavir Dose Defining Study</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>